InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $3.040 0.25 (8.96%)+
Announcement
Release
18 Aug 2026 8:12AM
Price at Release
$2.790
Full Release
download
Summary
The Appendix 4E for Cogstate Limited for the fiscal year ending 30 June 2026, highlights a significant increase in revenue and profitability. Total revenue from ordinary activities rose by 14.6% to USD 60.86 million, with clinical trials contributing USD 58.37 million, marking a 15.4% increase from the previous year. The company reported a net profit after tax of USD 11.9 million, a 17.3% rise compared to the previous year. Notably, Cogstate executed new sales contracts worth USD 89 million, a substantial 116% increase year-on-year. The total contracted future revenue increased by 32% to USD 118.5 million. The company declared a fully franked final dividend of AUD 0.04 per share, doubling from the previous year. Employment expenses saw a rise, with the number of full-time equivalent employees growing to 165.5. The financial report was audited without modification.
Key Points
  • Total revenue increased by 14.6% to USD 60.86 million.
  • Clinical trials revenue was USD 58.37 million, up 15.4%.
  • Net profit after tax was USD 11.9 million, a 17.3% increase.
  • USD 89 million worth of new sales contracts executed, a 116% increase.
  • Total contracted future revenue rose by 32% to USD 118.5 million.
  • Fully franked final dividend declared at AUD 0.04 per share.
  • Number of full-time equivalent employees increased to 165.5.
  • The financial report was audited without any modifications.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.